Browse our archive of webinars on pharmaceutical and biomedical research from collaborations between pharmaceutical companies, government, biotechnology companies and academia to create new drug discovery opportunities.
One-third of FDA-approved drugs target G protein-coupled receptors (GPCRs), transmembrane cell surface proteins that recognize small molecules and polypeptides with diverse chemical scaffolds...
Recent advances in DNA sequencing and omics-based capabilities are revealing incredible therapeutic opportunities and quickly transforming drug discovery. Molecularly targeted drugs aim to e...
Over the past 25 years surgically dependent animal models have expanded from a small, almost niche area in pharmaceutical research to an important component of most research portfolios. In t...
Structure based drug design is now well established as a highly efficient approach in pharmaceutical research. The approach uses atomic level detail structures of target proteins, most...
The last two decades have seen an explosion in the volume of oncology data generated using next-generation sequencing (NGS) and multi-omics techniques. As a result, there is a growing need fo...
The path form biomarker discovery to conversion to a clinically useful companion diagnostic test presents many challenges. The talk will outline the regulatory requirements to developing a su...
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of metabolic disorders affecting 25% of our global population. 20% of NAFLD patients go on to develop Non-alcoholic steatohepatitis (N...
Therapies that activate the host immune system have shown tremendous promise for a wide variety of solid tumors. However, in most cancer types, fewer than half of patients respond to these th...
Novel annotated Patient-Derived tumor Xenografts (PDX) propagated in immunodeficient mice and Organoids (PDO) in Matrigel have become essential models to study inter- and intra-tumor heterog...
With an increasing push to improve safety, efficacy, and efficiency throughout the drug development pipeline, researchers are evermore looking to improve the predictive capacity of their in...
Heart failure (HF) is a major problem for our contemporary societies in terms of prevalence, mortality and cost. Natriuretic peptides are recognized biomarkers for the diagnosis of HF but als...
Isolated hepatocytes or their enzymes comprise the basis of most in vitro DMPK and toxicity assays used to predict human hepatic outcomes. Because hepato-specific functions are typically lost...
Current drug discovery workflows are inefficient. 90% of therapeutic agents reaching clinical trials fail, predominantly because traditional laboratory experiments fail to adequately predict...
Dramatic responses observed with targeted agents in the ‘right’ genomic context have fueled large scale sequencing efforts to identify ‘effective’ treatments for a giv...
The Chain of Custody in our labs is the unbroken link between the objects used in your research: your people, the animal models, the cell lines, reagents, compounds; the lab instruments and d...
There is an acute shortage of organs due to disease, trauma, congenital defects, and most importantly, age related maladies. The synthetic materials used in tissue engineering applications to...
Image analysis in a real-world situation rarely involves solving a single unchanging problem. Modern tools need to be flexible and adaptable not only to solve todays problems but to support...
Second harmonic generation (SHG) is a biophysical method that sensitively measures real-time conformational change of biomolecules attached to membranes. SHG has recently been applied to dete...
The OrganoPlate is a microtiterplate based Organ-on-a-Chip platform for high throughput drug safety and efficacy screening. It contains up to 96 cell culture chambers that allow co-culture o...
Over the last few years, the space of advanced in vitro models has grown dramatically as researchers look to better mimic the in vivo environment within inexpensive and high throughput in vi...
Recent clinical successes in cancer genome-inspired personalized medicine have been a major breakthrough in drug discovery. However, 98% of the patients have an incomplete therapeutic respons...
The distinction between "complementary" and "companion" diagnostics tests confuse many physicians and healthcare professionals. Panelists Professor Thomas Webster (Northea...
Surgery is the first line of treatment for Stage III melanoma. Often adjuvant therapy is administered post-surgery, which can include weeks of radiation, chemotherapy, targeted drug therapy,...
Precision medicine allows for prediction of drug response and tailoring drug therapy based on genetic variability. This talk will provide examples of precision medicine initiatives at the Uni...
Multiplexing IHC is a technique that is increasing in demand as more and more researchers and physicians are being tasked with doing more with less. With multiplexing, you have the advantage...
Studies in drug development and on hematological and solid Tumors with a Thymidine Kinase 1 immunoassayThere are many tumor biomarkers but, they mostly reflect tumor mass or past growth,...
The Human Neutrophil Lipocalin (HNL) also called NGAL, Lipocalin 2 etc. is produced by and secreted from epithelial cells and neutrophil granulocytes. In blood HNL exists in several molecula...
One-third of FDA-approved drugs target G protein-coupled receptors (GPCRs), transmembrane cell surface proteins that recognize small molecules and polypeptides with diverse chemical scaffolds...
